Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shire exercises option on adenosine A2A antagonist candidate for CNS

This article was originally published in Scrip

Executive Summary

Shire has exercised its exclusive option to license a novel adenosine A2A antagonist discovered by Heptares that is currently in preclinical development. Under the agreement Heptares has granted Shire an exclusive licence to worldwide development and commercial rights to A2A antagonists discovered by Heptares. Heptares receives an upfront option fee and is also eligible to receive milestone payments up to $190 million plus royalties on product sales. Further terms are not being disclosed.

Advertisement
Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC016672

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel